A selective COX-2 inhibitor, meloxicam, as a treatment option in patients with juvenile idiopathic arthritis and gastrointestinal side effects from naproxen.
Foeldvari
I
I
D015746:Abdominal Pain / Q000139:chemically induced*; D000293:Adolescent; D000328:Adult; D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007596:Joints / Q000473:pathology / Q000503:physiopathology; D008297:Male; D000077239:Meloxicam; D009288:Naproxen / Q000009:adverse effects*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013843:Thiazines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
D016861:Cyclooxygenase Inhibitors; D013843:Thiazines; D013844:Thiazoles; D009288:Naproxen; D000077239:Meloxicam